Overview
Background
Associate Professor Paul Griffin is the Director of Infectious Diseases at Mater Health Services in Brisbane and Associate Professor of Medicine at the University of Queensland Medical School. He has fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia and from the Australasian College of Tropical Medicine.
Paul is the Principal Investigator and Medical Director at Nucleus Network, a specialized contract research organisation specializing in early and late phase trials in infectious diseases where he has been the principal investigator on in excess of 125 clinical trials, predominantly in Infectious Diseases including novel vaccines and Malaria human challenge studies. This includes 8 vaccines for COVID-19 and a number of COVID-19 therapies.
As a Clinical Microbiologist, he maintains an active interest in diagnostic microbiology with a focus on clinical applications of faecal microbiome metagenomic sequencing.
In addition to a teaching role at the University of Queensland, Paul is also the chair of the Advanced Training Committee in Infectious Diseases with the Royal Australasian College of Physicians, the committee that oversees the training of Infectious Diseases specialists in Australia.
Finally, as a director and scientific advisory board member of the immunisation coalition, Paul has an active interest in vaccine education and advocacy and has become a trusted media authority and spokesperson across the nation during the COVID-19 pandemic.
Availability
- Professor Paul Griffin is:
- Available for supervision
- Media expert
Fields of research
Research impacts
While performing vital clinical and research duties, he has also devoted time to inform, educate and reassure the community via a wide range of media appearances. He has featured regularly on prominent Australian programs across television, radio, print and online including The Project, Sunrise, Today Show, A Current Affair, and internationally including Canada’s CTV and the BBC.
Works
Search Professor Paul Griffin’s works on UQ eSpace
2022
Book
Frontiers of COVID-19: Scientific and clinical aspects of the novel coronavirus 2019
Sasan Adibi, Paul Griffin, Melvin Sanicas, Maryam Rashidi and Francesco Lanfranchi eds. (2022). Frontiers of COVID-19: Scientific and clinical aspects of the novel coronavirus 2019. Cham, Switzerland: Springer. doi: 10.1007/978-3-031-08045-6
2022
Journal Article
Japanese encephalitis - a recent rise in Australian cases
Armstrong, Mark, Grey, Victoria and Griffin, Paul (2022). Japanese encephalitis - a recent rise in Australian cases. Medicine Today, 23 (8), 49-53.
2022
Journal Article
Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial
Evans, Thomas G, Bussey, Louise, Eagling-Vose, Elizabeth, Rutkowski, Kathryn, Ellis, Chris, Argent, Chris, Griffin, Paul, Kim, Joshua, Thackwray, Susan, Shakib, Sepehr, Doughty, Julia, Gillies, John, Wu, Jian, Druce, Julian, Pryor, Melinda and Gilbert, Sarah (2022). Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial. The Lancet Infectious Diseases, 22 (6), 857-866. doi: 10.1016/S1473-3099(21)00702-7
2022
Journal Article
Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium
Pinto, Andreia L., Rai, Ranjit K., Brown, Jonathan C., Griffin, Paul, Edgar, James R., Shah, Anand, Singanayagam, Aran, Hogg, Claire, Barclay, Wendy S., Futter, Clare E. and Burgoyne, Thomas (2022). Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium. Nature Communications, 13 (1) 1609, 1-14. doi: 10.1038/s41467-022-29255-y
2022
Journal Article
Safety, tolerability, pharmacokinetics, and pharmacodynamics of coadministered Ruxolitinib and Artemether-Lumefantrine in healthy adults
Chughlay, M. Farouk, Barnes, Karen I., El Gaaloul, Myriam, Abla, Nada, Möhrle, Jörg J., Griffin, Paul, van Giersbergen, Paul, Reuter, Stephanie E., Schultz, Hayley B., Kress, Anita, Tapley, Peter, Webster, Rebecca A., Wells, Timothy, McCarthy, James S., Barber, Bridget E., Marquart, Louise, Boyle, Michelle J., Engwerda, Christian R. and Chalon, Stephan (2022). Safety, tolerability, pharmacokinetics, and pharmacodynamics of coadministered Ruxolitinib and Artemether-Lumefantrine in healthy adults. Antimicrobial Agents and Chemotherapy, 66 (1) e01584-21, e0158421. doi: 10.1128/AAC.01584-21
2022
Book Chapter
The Road Ahead (Editors)
Adibi, Sasan, Griffin, Paul, Sanicas, Melvin, Rashidi, Maryam and Lanfranchi, Francesco (2022). The Road Ahead (Editors). Frontiers of COVID-19: Scientific and Clinical Aspects of the Novel Coronavirus 2019. (pp. 639-650) edited by Sasan Adibi, Paul Griffin, Melvin Sanicas, Maryam Rashidi and Francesco Lanfranchi. Cham, Switzerland: Springer Nature Switzerland. doi: 10.1007/978-3-031-08045-6_31
2021
Journal Article
Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine
Webster, Rebecca, Sekuloski, Silvana, Odedra, Anand, Woolley, Stephen, Jennings, Helen, Amante, Fiona, Trenholme, Katharine R., Healer, Julie, Cowman, Alan F., Eriksson, Emily M., Sathe, Priyanka, Penington, Jocelyn, Blanch, Adam J., Dixon, Matthew W. A., Tilley, Leann, Duffy, Michael F., Craig, Alister, Storm, Janet, Chan, Jo-Anne, Evans, Krystal, Papenfuss, Anthony T., Schofield, Louis, Griffin, Paul, Barber, Bridget E., Andrew, Dean, Boyle, Michelle J., de Labastida Rivera, Fabian, Engwerda, Christian and McCarthy, James S. (2021). Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine. BMC Medicine, 19 (1) 293, 293. doi: 10.1186/s12916-021-02150-x
2021
Journal Article
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
Chappell, Keith J., Mordant, Francesca L., Li, Zheyi, Wijesundara, Danushka K., Ellenberg, Paula, Lackenby, Julia A., Cheung, Stacey T. M., Modhiran, Naphak, Avumegah, Michael S., Henderson, Christina L., Hoger, Kym, Griffin, Paul, Bennet, Jillian, Hensen, Luca, Zhang, Wuji, Nguyen, Thi H. O., Marrero-Hernandez, Sara, Selva, Kevin J., Chung, Amy W., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Nicholson, Suellen, Corby, Stavroula, Holgate, Thomas, Wines, Bruce D., Hogarth, P Mark, Kedzierska, Katherine ... Munro, Trent P. (2021). Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Infectious Diseases, 21 (10), 1383-1394. doi: 10.1016/S1473-3099(21)00200-0
2021
Journal Article
A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients
Yamada, Miko, Miller, Dennis M., Lowe, Melinda, Rowe, Casey, Wood, Dominic, Soyer, H. Peter, Byrnes-Blake, Kelly, Parrish-Novak, Julia, Ishak, Laura, Olson, James M., Brandt, Gordon, Griffin, Paul, Spelman, Lynda and Prow, Tarl W. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemporary Clinical Trials Communications, 23 100830, 1-6. doi: 10.1016/j.conctc.2021.100830
2021
Journal Article
Addressing the crisis of congenital syphilis: Key findings from an evaluation of the management of syphilis in pregnancy and the newborn in South‐East Queensland
Wu, Mandy, Seel, Mandy, Britton, Sumudu, Dean, Judith A., Lazarou, Mattea, Safa, Huda, Griffin, Paul and Nourse, Clare (2021). Addressing the crisis of congenital syphilis: Key findings from an evaluation of the management of syphilis in pregnancy and the newborn in South‐East Queensland. Australian and New Zealand Journal of Obstetrics and Gynaecology, 62 (1) ajo.13424, 91-97. doi: 10.1111/ajo.13424
2021
Journal Article
Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study
Krishnan, Ravi, Duiker, Melanie, Rudd, Penny A., Skerrett, Donna, Pollard, James G. D., Siddel, Carolyn, Rifat, Rifat, Ng, Jennifer H. K., Georgius, Peter, Hererro, Lara J. and Griffin, Paul (2021). Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study. BMC Musculoskeletal Disorders, 22 (1) 271. doi: 10.1186/s12891-021-04123-w
2021
Journal Article
Defining the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparum
McCarthy, James S., Abd-Rahman, Azrin N., Collins, Katharine A., Marquart, Louise, Griffin, Paul, Kummel, Anne, Fuchs, Aline, Winnips, Cornelis, Mishra, Vishal, Csermak-Renner, Katalin, Jain, J. Prakash and Gandhi, Preetam (2021). Defining the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 65 (2) e01423-20. doi: 10.1128/aac.01423-20
2020
Journal Article
Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
Keech, Cheryl, Albert, Gary, Cho, Iksung, Robertson, Andreana, Reed, Patricia, Neal, Susan, Plested, Joyce S., Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Haixia, Smith, Gale, Patel, Nita, Frieman, Matthew B., Haupt, Robert E., Logue, James, McGrath, Marisa, Weston, Stuart, Piedra, Pedro A., Desai, Chinar, Callahan, Kathleen, Lewis, Maggie, Price-Abbott, Patricia, Formica, Neil, Shinde, Vivek, Fries, Louis, Lickliter, Jason D., Griffin, Paul, Wilkinson, Bethanie and Glenn, Gregory M. (2020). Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. The New England Journal of Medicine, 383 (24), 2320-2332. doi: 10.1056/NEJMoa2026920
2020
Journal Article
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults
Aliprantis, Antonios O., Shaw, Christine A., Griffin, Paul, Farinola, Nicholas, Railkar, Radha A., Cao, Xin, Liu, Wen, Sachs, Jeffrey R., Swenson, Christine J., Lee, Heather, Cox, Kara S., Spellman, Daniel S., Winstead, Colleen J., Smolenov, Igor, Lai, Eseng, Zaks, Tal, Espeseth, Amy S. and Panther, Lori (2020). A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human Vaccines and Immunotherapeutics, 17 (5), 1-14. doi: 10.1080/21645515.2020.1829899
2020
Journal Article
Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study
Henderson, A., Paterson, D. L., Chatfield, M. D., Tambyah, P. A., Lye, D. C., De, P. P., Lin, R. T. P., Chew, K. L., Yin, M., Lee, T. H., Yilmaz, M., Cakmak, R., Alenazi, T. H., Arabi, Y. M., Falcone, M., Bassetti, M., Righi, E., Rogers, B.A., Kanj, S. S., Bhally, H., Iredell, J., Mendelson, M., Boyles, T. H., Looke, D. F. M., Runnegar, N. J., Miyakis, S., Walls, G., AI Khamis, M., Zikri, A. ... For the MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN) (2020). Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study. Clinical Infectious Diseases, 73 (11), e3842-e3850. doi: 10.1093/cid/ciaa1479
2020
Journal Article
Pharmacokinetics and pharmacodynamics of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: a randomized, double-blind trial
Lickliter, Jason, Kanceva, Radmila, Vincent, Emmanuelle, Schueler, Armin, Harrison-Moench, Eleanor, Yue, Corinne Seng, Stahl, Michael, Ullmann, Martin, Ghori, Vishal and Griffin, Paul (2020). Pharmacokinetics and pharmacodynamics of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: a randomized, double-blind trial. Clinical Therapeutics, 42 (8), 1508-1518.e1. doi: 10.1016/j.clinthera.2020.05.020
2020
Journal Article
Antimalarial activity of artefenomel against asexual parasites and transmissible gametocytes during experimental blood-stage Plasmodium vivax infection
Collins, Katharine A., Abd-Rahman, Azrin N., Marquart, Louise, Ballard, Emma, Gobeau, Nathalie, Griffin, Paul, Chalon, Stephan, Möhrle, Jörg J. and McCarthy, James S. (2020). Antimalarial activity of artefenomel against asexual parasites and transmissible gametocytes during experimental blood-stage Plasmodium vivax infection. The Journal of Infectious Diseases, 225 (6), 1062-1069. doi: 10.1093/infdis/jiaa287
2020
Journal Article
Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study
Playford, Elliott Geoffrey, Munro, Trent, Mahler, Stephen M., Elliott, Suzanne, Gerometta, Michael, Hoger, Kym L., Jones, Martina L., Griffin, Paul, Lynch, Kathleen D., Carroll, Heidi, El Saadi, Debra, Gilmour, Margaret E., Hughes, Benjamin, Hughes, Karen, Huang, Edwin, de Bakker, Christopher, Klein, Reuben, Scher, Mark G., Smith, Ina L., Wang, Lin-Fa, Lambert, Stephen B., Dimitrov, Dimiter S., Gray, Peter P. and Broder, Christopher C. (2020). Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. The Lancet Infectious Diseases, 20 (4), 445-454. doi: 10.1016/S1473-3099(19)30634-6
2020
Journal Article
A single-dose combination study with the experimental antimalarials artefenomel and DSM265 to determine safety and antimalarial activity against blood-stage Plasmodium falciparum in healthy volunteers
McCarthy, James S., Rückle, Thomas, Elliott, Suzanne L., Ballard, Emma, Collins, Katharine A., Marquart, Louise, Griffin, Paul, Chalon, Stephan and Möhrle, Jörg J. (2020). A single-dose combination study with the experimental antimalarials artefenomel and DSM265 to determine safety and antimalarial activity against blood-stage Plasmodium falciparum in healthy volunteers. Antimicrobial Agents and Chemotherapy, 64 (1) e01371-19, e01371-19. doi: 10.1128/AAC.01371-19
2019
Journal Article
Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: a randomized double blinded phase I/IIa trial
Chandra, Janin, Woo, Wai-Ping, Dutton, Julie L., Xu, Yan, Li, Bo, Kinrade, Sally, Druce, Julian, Finlayson, Neil, Griffin, Paul, Laing, Kerry J., Koelle, David M. and Frazer, Ian H. (2019). Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: a randomized double blinded phase I/IIa trial. PLoS One, 14 (12) e0226320, 1-20. doi: 10.1371/journal.pone.0226320
Funding
Past funding
Supervision
Availability
- Professor Paul Griffin is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
Contact Professor Paul Griffin directly for media enquiries about:
- COVID-19
- Infectious Diseases
- microbiology
- Vaccines
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: